Zelboraf Patent Expiration

ZELBORAF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8143271 HOFFMANN LA ROCHE NA
Jun, 2026

(1 year, 11 months from now)

US7504509 HOFFMANN LA ROCHE Compounds and methods for development of Ret modulators
Oct, 2026

(2 years from now)

US7863288 HOFFMANN LA ROCHE NA
Jun, 2029

(4 years from now)

US8741920 HOFFMANN LA ROCHE Process for the manufacture of pharmaceutically active compounds
Jul, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470818 HOFFMANN LA ROCHE NA
Aug, 2026

(2 years from now)

US9447089 HOFFMANN LA ROCHE Compositions and uses thereof
Jun, 2032

(7 years from now)



Zelboraf is a drug owned by Hoffmann La Roche Inc. It is used for treating patients with unresectable or metastatic melanoma with BRAFV600E mutation. Zelboraf uses Vemurafenib as an active ingredient. Zelboraf was launched by Hoffmann La Roche in 2011. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 06, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 17, 2016
Orphan Drug Exclusivity(ODE-13) Aug 17, 2018
Orphan Drug Exclusivity(ODE) Aug 17, 2018
M(M-184) Aug 31, 2019
New Indication(I-757) Nov 06, 2020
Orphan Drug Exclusivity(ODE-158) Nov 06, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using VEMURAFENIB ingredient

NCE-1 date: 18 August, 2015

Market Authorisation Date: 17 August, 2011

Treatment: Treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test

Dosage: TABLET

More Information on Dosage

ZELBORAF family patents

Family Patents